Modified Thresholds for Fibrosis Risk Scores in Nonalcoholic Fatty Liver Disease Are Necessary in the Obese

Overview

Journal Obes Surg

Date 2016 May 26

PMID 27220852

Citations 14

Authors

Geraldine J Ooi

Paul R Burton

Lisa Doyle

John M Wentworth

Prithi S Bhathal

Ken Sikaris

Michael A Cowley

Stuart K Roberts

William Kemp

Paul E OBrien

Wendy A Brown

Affiliations

Soon will be listed here.

Abstract

Background: Obesity and its related comorbidities are significant risk factors for nonalcoholic fatty liver disease (NAFLD). Liver fibrosis is the major determinant of long-term outcomes in NAFLD. A non-invasive tool that accurately identifies obese patients at elevated risk of liver fibrosis would be of significant value. Fibrosis risk scores in patients with NAFLD have been proposed but have not been validated in obese populations. We aimed to validate established simple fibrosis scores in bariatric surgical patients.

Methods: We conducted a prospective study of 107 consecutive high-risk obese patients undergoing primary bariatric surgery. Proposed fibrosis scores (NAFLD fibrosis score; body mass index (BMI), aspartate aminotransferase (AST)/alanine aminotransferase ratio (ALT), and diabetes (BARD); Fibrosis-4 (FIB-4); Forn; and AST to platelet ratio index) were calculated and compared hepatic fibrosis determined by histology of intraoperative liver biopsies. Accuracy was determined, and fibrosis score thresholds were optimized. These modified thresholds were then validated in an independent bariatric surgical population.

Results: Liver biopsies were available in 101 patients. Sixty-eight patients had some degree of fibrosis, with 23 patients (23 %) having significant fibrosis (F2-4). The Forn score best predicted significant fibrosis (area under the receiver operator characteristic curve (AUROC) 0.724, p = 0.001). With standard thresholds, the sensitivity for the Forn score for identification of significant fibrosis (F2-4) was 0 %. Using modified thresholds of 3.5, the sensitivity and negative predictive value increased to 85.7 and 94.7 %. This threshold was applied to an independent validation cohort with good accuracy.

Conclusions: Fibrosis risk scores using simple markers have moderate success at delineating obese patients with significant NAFLD-related fibrosis. Thresholds, however, need to be lowered to maximize diagnostic accuracy in this cohort.

Citing Articles

Deep proteome profiling of metabolic dysfunction-associated steatotic liver disease.

Boel F, Akimov V, Teuchler M, Terkelsen M, Wernberg C, Larsen F Commun Med (Lond). 2025; 5(1):56.

PMID: 40032974 PMC: 11876662. DOI: 10.1038/s43856-025-00780-3.

Machine Learning Models for Predicting Significant Liver Fibrosis in Patients with Severe Obesity and Nonalcoholic Fatty Liver Disease.

Lu C, Wang W, Li Y, Chang I, Chen C, Su C Obes Surg. 2024; 34(12):4393-4404.

PMID: 39448457 DOI: 10.1007/s11695-024-07548-z.

Prospective Study to Analyze the Concordance Between a Standardized Visual Method With Pathology to stratify Nonalcoholic Fatty Liver Disease in Cadaveric Liver Grafts Evaluated for Transplantation.

Sampaio-Neto J, Nicoluzzi J, Luvison Gomes da Silva L, Billo L, de Padua Peppe-Neto A, Dall Asta L Transplant Direct. 2023; 9(11):e1540.

PMID: 37899779 PMC: 10602502. DOI: 10.1097/TXD.0000000000001540.

Accuracy of FIB-4 to Detect Elevated Liver Stiffness Measurements in Patients with Non-Alcoholic Fatty Liver Disease: A Cross-Sectional Study in Referral Centers.

Vigano M, Pugliese N, Cerini F, Turati F, Cimino V, Ridolfo S Int J Mol Sci. 2022; 23(20).

PMID: 36293345 PMC: 9604259. DOI: 10.3390/ijms232012489.

The Utility and Diagnostic Accuracy of Transient Elastography in Adults with Morbid Obesity: A Prospective Study.

Ali A, Al Juboori A, Petroski G, Diaz-Arias A, Syed-Abdul M, Wheeler A J Clin Med. 2022; 11(5).

PMID: 35268293 PMC: 8911197. DOI: 10.3390/jcm11051201.

References

Dixon J, Bhathal P, OBrien P . Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology. 2001; 121(1):91-100. DOI: 10.1053/gast.2001.25540. View

Harrison S, Oliver D, ARNOLD H, Gogia S, Neuschwander-Tetri B . Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut. 2008; 57(10):1441-7. DOI: 10.1136/gut.2007.146019. View

Alberti K, Zimmet P, Shaw J . Metabolic syndrome--a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med. 2006; 23(5):469-80. DOI: 10.1111/j.1464-5491.2006.01858.x. View

Feijo S, de Castro Lima J, Oliveira M, Patrocinio R, Moura-Junior L, Campos A . The spectrum of non alcoholic fatty liver disease in morbidly obese patients: prevalence and associate risk factors. Acta Cir Bras. 2013; 28(11):788-93. DOI: 10.1590/s0102-86502013001100008. View

Ratziu V, Giral P, Charlotte F, Bruckert E, Thibault V, Theodorou I . Liver fibrosis in overweight patients. Gastroenterology. 2000; 118(6):1117-23. DOI: 10.1016/s0016-5085(00)70364-7. View

Angulo P, Keach J, Batts K, Lindor K . Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology. 1999; 30(6):1356-62. DOI: 10.1002/hep.510300604. View

Dvorak K, Stritesky J, Petrtyl J, Vitek L, Sroubkova R, Lenicek M . Use of non-invasive parameters of non-alcoholic steatohepatitis and liver fibrosis in daily practice--an exploratory case-control study. PLoS One. 2014; 9(10):e111551. PMC: 4211730. DOI: 10.1371/journal.pone.0111551. View

Shalhub S, Parsee A, Gallagher S, Haines K, Willkomm C, Brantley S . The importance of routine liver biopsy in diagnosing nonalcoholic steatohepatitis in bariatric patients. Obes Surg. 2004; 14(1):54-9. DOI: 10.1381/096089204772787293. View

Raszeja-Wyszomirska J, Szymanik B, Lawniczak M, Kajor M, Chwist A, Milkiewicz P . Validation of the BARD scoring system in Polish patients with nonalcoholic fatty liver disease (NAFLD). BMC Gastroenterol. 2010; 10:67. PMC: 2905324. DOI: 10.1186/1471-230X-10-67. View

10.

Kleiner D, Berk P, Hsu J, Courcoulas A, Flum D, Khandelwal S . Hepatic pathology among patients without known liver disease undergoing bariatric surgery: observations and a perspective from the longitudinal assessment of bariatric surgery (LABS) study. Semin Liver Dis. 2014; 34(1):98-107. PMC: 4139971. DOI: 10.1055/s-0034-1371083. View

11.

Cui J, Ang B, Haufe W, Hernandez C, Verna E, Sirlin C . Comparative diagnostic accuracy of magnetic resonance elastography vs. eight clinical prediction rules for non-invasive diagnosis of advanced fibrosis in biopsy-proven non-alcoholic fatty liver disease: a prospective study. Aliment Pharmacol Ther. 2015; 41(12):1271-80. PMC: 4532628. DOI: 10.1111/apt.13196. View

12.

Olefsky J, Glass C . Macrophages, inflammation, and insulin resistance. Annu Rev Physiol. 2010; 72:219-46. DOI: 10.1146/annurev-physiol-021909-135846. View

13.

Angulo P, Hui J, Marchesini G, Bugianesi E, George J, Farrell G . The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007; 45(4):846-54. DOI: 10.1002/hep.21496. View

14.

Gholam P, Kotler D, Flancbaum L . Liver pathology in morbidly obese patients undergoing Roux-en-Y gastric bypass surgery. Obes Surg. 2002; 12(1):49-51. DOI: 10.1381/096089202321144577. View

15.

Kleiner D, Brunt E, Van Natta M, Behling C, Contos M, Cummings O . Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005; 41(6):1313-21. DOI: 10.1002/hep.20701. View

16.

Ekstedt M, Hagstrom H, Nasr P, Fredrikson M, Stal P, Kechagias S . Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology. 2014; 61(5):1547-54. DOI: 10.1002/hep.27368. View

17.

Kim D, Kim W, Talwalkar J, Kim H, Ehman R . Advanced fibrosis in nonalcoholic fatty liver disease: noninvasive assessment with MR elastography. Radiology. 2013; 268(2):411-9. PMC: 3721049. DOI: 10.1148/radiol.13121193. View

18.

Ruffillo G, Fassio E, Alvarez E, Landeira G, Longo C, Dominguez N . Comparison of NAFLD fibrosis score and BARD score in predicting fibrosis in nonalcoholic fatty liver disease. J Hepatol. 2010; 54(1):160-3. DOI: 10.1016/j.jhep.2010.06.028. View

19.

Subasi C, Aykut U, Yilmaz Y . Comparison of noninvasive scores for the detection of advanced fibrosis in patients with nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol. 2014; 27(2):137-41. DOI: 10.1097/MEG.0000000000000255. View

20.

Shah A, Lydecker A, Murray K, Tetri B, Contos M, Sanyal A . Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2009; 7(10):1104-12. PMC: 3079239. DOI: 10.1016/j.cgh.2009.05.033. View